161 related articles for article (PubMed ID: 33012095)
21. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
22. Vemurafenib and cobimetinib in BRAF-mutated melanoma.
Rahman A
Lancet Oncol; 2014 Nov; 15(12):e535. PubMed ID: 25602110
[No Abstract] [Full Text] [Related]
23. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract][Full Text] [Related]
24. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA
Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523
[TBL] [Abstract][Full Text] [Related]
25. Immunosuppressant-induced acneiform eruption of the breast.
Mackesy MM; Selhorst C; Raza S
Breast J; 2014; 20(6):650-2. PubMed ID: 25229395
[TBL] [Abstract][Full Text] [Related]
26. Gene Expression Profiling in
Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
[No Abstract] [Full Text] [Related]
27. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF
Lewis K; Hauschild A; Larkin J; Ribas A; Flaherty KT; McArthur GA; Dréno B; McKenna E; Zhu Q; Mun Y; Ascierto PA
Eur J Cancer; 2019 Jul; 116():45-55. PubMed ID: 31173962
[TBL] [Abstract][Full Text] [Related]
28. [Vemurafenib-induced radiation recall dermatitis].
Greliak A; Le Guern A; Bataille M; Lebas D; Wiart T; Modiano P
Ann Dermatol Venereol; 2019 May; 146(5):382-384. PubMed ID: 30981540
[TBL] [Abstract][Full Text] [Related]
29. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Lewis KD; Larkin J; Ribas A; Flaherty KT; McArthur GA; Ascierto PA; Dréno B; Yan Y; Wongchenko M; McKenna E; Zhu Q; Mun Y; Hauschild A
Br J Cancer; 2019 Oct; 121(7):522-528. PubMed ID: 31417188
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
Hopkins AM; Rathod AD; Rowland A; Kichenadasse G; Sorich MJ
BMC Cancer; 2020 Feb; 20(1):157. PubMed ID: 32103736
[TBL] [Abstract][Full Text] [Related]
31. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
32. MEK Retinopathy. Clinical case reports.
Rocha Cabrera P; Quijada Fumero E; Losada Castillo MJ; Abreu Reyes JA; Lorenzo Morales J
Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):42-46. PubMed ID: 28506716
[TBL] [Abstract][Full Text] [Related]
33. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
Diamantopoulos PT; Lakiotaki E; Kyriakakis G; Gogas H
Melanoma Res; 2020 Apr; 30(2):206-208. PubMed ID: 31157737
[TBL] [Abstract][Full Text] [Related]
34. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
35. RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Kaya G; Saxer-Sekulic N; Kaya A; Sorg O; Boespflug A; Thomas L; Saurat JH
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1368-1372. PubMed ID: 29575357
[TBL] [Abstract][Full Text] [Related]
36. A status report on drug-associated acne and acneiform eruptions.
Momin SB; Peterson A; Del Rosso JQ
J Drugs Dermatol; 2010 Jun; 9(6):627-36. PubMed ID: 20645524
[TBL] [Abstract][Full Text] [Related]
37. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
van der Hiel B; Haanen JBAG; Stokkel MPM; Peeper DS; Jimenez CR; Beijnen JH; van de Wiel BA; Boellaard R; van den Eertwegh AJM;
BMC Cancer; 2017 Sep; 17(1):649. PubMed ID: 28915798
[TBL] [Abstract][Full Text] [Related]
38. Two cases of pneumonitis induced by targeted therapy.
Lafabregue E; Arnault JP; Auquier M; Magois E; Chaby G; Lok C
Melanoma Res; 2019 Aug; 29(4):441-443. PubMed ID: 31260421
[TBL] [Abstract][Full Text] [Related]
39. Aripiprazole-induced acneiform eruption.
Mishra B; Praharaj SK; Prakash R; Sinha VK
Gen Hosp Psychiatry; 2008; 30(5):479-81. PubMed ID: 18774434
[TBL] [Abstract][Full Text] [Related]
40. DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem.
Ros J; Muñoz-Couselo E
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30275021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
